Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 106 participants.
Also called NCT05241431
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 106 participants
- Registry
-
NCT05241431
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT05241431. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-12 (actual); primary completion 2024-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
- Acronym
- DAPAS
- Condition
- Aortic Stenosis
- Condition
- Left Ventricle Hypertrophied
- Intervention (Drug)
- SGLT2 inhibitor
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Aarhus
- Collaborator
- Aarhus University Hospital
Record details
- Record id
cardio:ct-nct05241431- Content hash
21b35158948c27816869797b76c070a6c312ae36aa5267f1d64d5de904b66881